RA0317

antibody from Oursmab

Targeting: IGF1R CD221, IGFIR, IGFR, JTK13, MGC18216

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0317

Provider

Oursmab

Product name

Dalotuzumab (Biosimilar Reference Antibody) (IGF1R)

Antibody type

Monoclonal

Description

Dalotuzumab (also known as MK-0646) is an investigational humanized monoclonal antibody that was developed as a targeted therapy for cancer, specifically for tumors dependent on insulin-like growth factor (IGF) signaling. It functioned as an insulin-like growth factor 1 receptor (IGF-1R) antagonist, designed to block a key pathway involved in tumor cell growth, survival, and resistance to therapy. Clinical trials evaluated its efficacy, primarily in combination with other agents (such as chemotherapy or EGFR inhibitors), in patients with metastatic colorectal cancer, hormone receptor-positive breast cancer, and other solid tumors. Despite a strong preclinical rationale, its clinical development was ultimately discontinued after later-phase trials failed to demonstrate a significant survival benefit over standard treatments alone.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.